PF-07265028

· Pfizer

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PF-07265028, covering 2026-02-19 to 2026-02-19. Get the full timeline:

Most recent: Clinical Trial Update: PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors [Phase 1]